Oruka Therapeutics (NASDAQ:ORKA) Earns “Buy” Rating from HC Wainwright

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $45.00 target price on the stock. HC Wainwright’s price objective would suggest a potential upside of 116.87% from the company’s previous close.

ORKA has been the topic of several other reports. Leerink Partners assumed coverage on Oruka Therapeutics in a report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 target price on the stock. Lifesci Capital assumed coverage on Oruka Therapeutics in a report on Monday, September 16th. They set an “outperform” rating and a $41.00 target price on the stock. Leerink Partnrs upgraded Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th. Wedbush reiterated an “outperform” rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, November 19th. Finally, Stifel Nicolaus assumed coverage on Oruka Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $43.17.

Oruka Therapeutics Trading Up 1.2 %

NASDAQ:ORKA opened at $20.75 on Monday. Oruka Therapeutics has a 12 month low of $18.72 and a 12 month high of $53.88. The business’s 50 day moving average price is $26.16. The stock has a market cap of $726.25 million, a price-to-earnings ratio of -3.31 and a beta of 0.87.

Institutional Investors Weigh In On Oruka Therapeutics

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the 3rd quarter worth approximately $343,000. Frazier Life Sciences Management L.P. purchased a new stake in Oruka Therapeutics during the third quarter worth $11,699,000. Wellington Management Group LLP acquired a new stake in Oruka Therapeutics in the third quarter valued at $2,013,000. RTW Investments LP purchased a new position in shares of Oruka Therapeutics in the third quarter valued at $45,359,000. Finally, Redmile Group LLC acquired a new position in shares of Oruka Therapeutics during the 3rd quarter worth $10,091,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.